Resistance to HIV-1 integrase inhibitors: A structural perspective

Drug Resistance Updates

Volumn 13, Issue 4-5, 2010, Pages 139-150

  Mouscadet, Jean François ^a   Delelis, Olivier ^a   Marcelin, Anne Geneviève ^b   Tchertanov, Luba ^a  

^a Ecole Normale Superieure de Cachan   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

HIV 1; Integrase; Molecular modeling; Resistance; Strand transfer inhibitor

Indexed keywords

COBICISTAT; CYTOCHROME P450 INHIBITOR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GSK 12349572; INTEGRASE INHIBITOR; RALTEGRAVIR; RITONAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME CONFORMATION; ENZYME STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; PRIORITY JOURNAL; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION;

EID: 77956886199     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2010.05.001     Document Type: Article

References (101)

1. Agapkina J., Smolov M., Barbe S., Zubin E., Zatsepin T., Deprez E., Le Bret M., Mouscadet J.F., Gottikh M. Probing of HIV-1 integrase/DNA interactions using novel analogs of viral DNA. J. Biol. Chem. 2006, 281:11530-11540.
2. Asante-Appiah E., Skalka A.M. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv. Virus Res. 1999, 52:351-369.
3. Ason B., Knauss D.J., Balke A.M., Merkel G., Skalka A.M., Reznikoff W.S. Targeting Tn5 transposase identifies human immunodeficiency virus type 1 inhibitors. Antimicrob. Agents Chemother. 2005, 49:2035-2043.
4. Bar-Magen T., Sloan R.D., Faltenbacher V.H., Donahue D.A., Kuhl B.D., Oliveira M., Xu H., Wainberg M.A. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology 2009, 6:103.
5. Barreca M.L., De Luca L., Iraci N., Chimirri A. Binding mode prediction of strand transfer HIV-1 integrase inhibitors using Tn5 transposase as a plausible surrogate model for HIV-1 integrase. J. Med. Chem. 2006, 49:3994-3997.
6. Barreca M.L., Iraci N., De Luca L., Chimirri A. Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. Chem. Med. Chem. 2009, 4:1446-1456.
7. Barreca M.L., Lee K.W., Chimirri A., Briggs J.M. Molecular dynamics studies of the wild-type and double mutant HIV-1 integrase complexed with the 5CITEP inhibitor: mechanism for inhibition and drug resistance. Biophys. J. 2003, 84:1450-1463.
8. Bera S., Pandey K.K., Vora A.C., Grandgenett D.P. Molecular interactions between HIV-1 integrase and the two viral DNA ends within the synaptic complex that mediates concerted integration. J. Mol. Biol. 2009, 389:183-198.
9. Brigo A., Lee K.W., Fogolari F., Mustata G.I., Briggs J.M. Comparative molecular dynamics simulations of HIV-1 integrase and the T66I/M154I mutant: binding modes and drug resistance to a diketo acid inhibitor. Proteins 2005, 59:723-741.
10. Brown P.O. Integration of retroviral DNA. Curr. Top. Microbiol. Immunol. 1990, 157(19-48):19-48.
11. Bujacz G., Jaskolski M., Alexandratos J., Wlodawer A., Merkel G., Katz R.A., Skalka A.M. The catalytic domain of avian sarcoma virus integrase: conformation of the active-site residues in the presence of divalent cations. Structure 1996, 4:89-96.
12. Bujacz G., Alexandratos J., Wlodawer A., Merkel G., Andrake M., Katz R.A., Skalka A.M. Binding of different divalent cations to the active site of avian sarcoma virus integrase and their effects on enzymatic activity. J. Biol. Chem. 1997, 272:18161-18168.
13. Cai M., Zheng R., Caffrey M., Craigie R., Clore G.M., Gronenborn A.M. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat. Struct. Biol. 1997, 4:567-577.
14. Ceccherini-Silberstein F., Armenia D., D'Arrigo R., Vandebroucke I., Van Marck H., Rizzardini G., Narciso P., Antinori A., Stuyver L., Perno C.F. Primary mutations associated with resistance to raltegravir are not detectable by pyrosequencing in integrase inhibitors-naive patients. 17th Conference on Retroviruses and Opportunistic Infections (CROI) 2010, (abstract #566).
15. Ceccherini-Silberstein F., Malet I., D'Arrigo R., Antinori A., Marcelin A.G., Perno C.F. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev. 2009, 11:17-29.
16. Chen A., Weber I.T., Harrison R.W., Leis J. Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat ends. J. Biol. Chem. 2006, 281:4173-4182.
17. Chen X., Tsiang M., Yu F., Hung M., Jones G.S., Zeynalzadegan A., Qi X., Jin H., Kim C.U., Swaminathan S., et al. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. J. Mol. Biol. 2008, 380:504-519.
18. Chen Z., Yan Y., Munshi S., Li Y., Zugay-Murphy J., Xu B., Witmer M., Felock P., Wolfe A., Sardana V., et al. X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293)-an initial glance of the viral DNA binding platform. J. Mol. Biol. 2000, 296:521-533.
19. Cohen C., Shamblaw D., Ruane P., Elion R., DeJesus E., Liu H., Zhong L., Warren D., Kearney B., Chuck S. Single-tablet, fixed-dose regimen of elvitegravir/emtricitabine/tenofovir disoproxil fumarate/GS-9350 achieves a high rate of virologic suppression and GS-9350 is an effective booster. 17th Conference on Retroviruses and Opportunistic Infections (CROI) 2010, (abstract 58LB).
20. Cooper D.A., Steigbigel R.T., Gatell J.M., Rockstroh J.K., Katlama C., Yeni P., Lazzarin A., Clotet B., Kumar P.N., Eron J.E., et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 2008, 359:355-365.
21. Croxtall J.D., Keam S.J. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients. Drugs 2009, 69:1059-1075.
22. Davies D.R., Goryshin I.Y., Reznikoff W.S., Rayment I. Three-dimensional structure of the Tn5 synaptic complex transposition intermediate. Science 2000, 289:77-85.
23. De Luca L., Pedretti A., Vistoli G., Barreca M.L., Villa L., Monforte P., Chimirri A. Analysis of the full-length integrase-DNA complex by a modified approach for DNA docking. Biochem. Biophys. Res. Commun. 2003, 310:1083-1088.
24. Delelis O., Malet I., Na L., Tchertanov L., Calvez V., Marcelin A.G., Subra F., Deprez E., Mouscadet J.F. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res. 2009, 37:1193-1201.
25. Delelis O., Thierry S., Subra F., Simon F., Malet I., Alloui C., Sayon S., Calvez V., Deprez E., Marcelin A.G., et al. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob. Agents Chemother. 2010, 54:491-501.
26. Dhaked D.K., Verma J., Saran A., Coutinho E.C. Exploring the binding of HIV-1 integrase inhibitors by comparative residue interaction analysis (CoRIA). J. Mol. Model. 2009, 15:233-245.
27. Dolan J., Chen A., Weber I.T., Harrison R.W., Leis J. Defining the DNA substrate binding sites on HIV-1 integrase. J. Mol. Biol. 2009, 385:568-579.
28. Donahue D.A., Sloan R.D., Kuhl B.D., Bar-Magen T., Schader S.M., Wainberg M.A. Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob. Agents Chemother. 2010, 54:1047-1054.
29. Dyda F., Hickman A.B., Jenkins T.M., Engelman A., Craigie R., Davies D.R. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994, 266:1981-1986.
30. Eijkelenboom A.P., Lutzke R.A., Boelens R., Plasterk R.H., Kaptein R., Hard K. The DNA-binding domain of HIV-1 integrase has an SH3-like fold. Nat. Struct. Biol. 1995, 2:807-810.
31. Ellison V., Gerton J., Vincent K.A., Brown P.O. An essential interaction between distinct domains of HIV-1 integrase mediates assembly of the active multimer. J. Biol. Chem. 1995, 270:3320-3326.
32. Eron J., Andrade J., Zajdenverg R., Workman C., Cooper D., Young B., Xu X., Nguyen B.-Y., Leavitt R., Sklar P. Switching from stable lopinavir/ritonavir-based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24. 16th Conference on Retroviruses and Opportunistic Infections (CROI) 2009, (abstract 70aLB).
33. Espeseth A.S., Felock P., Wolfe A., Witmer M., Grobler J., Anthony N., Egbertson M., Melamed J.Y., Young S., Hamill T., et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:11244-11249.
34. Esposito D., Craigie R. Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J. 1998, 17:5832-5843.
35. Faure A., Calmels C., Desjobert C., Castroviejo M., Caumont-Sarcos A., Tarrago-Litvak L., Litvak S., Parissi V. HIV-1 integrase crosslinked oligomers are active in vitro. Nucleic Acids Res. 2005, 33:977-986.
36. Fenollar-Ferrer C., Carnevale V., Raugei S., Carloni P. HIV-1 integrase-DNA interactions investigated by molecular modelling. Comput. Math. Methods Med. 2008, 9:231-243.
37. Fransen S., Frantzell A., Gupta S., Petropoulos C., Huang W. Comparison of raltegravir susceptible and resistant viruses defines the contribution of secondary mutations to reductions in raltegravir susceptibility. 17th Conference on Retroviruses and Opportunisitic Infections (CROI) 2010, (abstract #556).
38. Gao K., Butler S.L., Bushman F. Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes. EMBO J. 2001, 20:3565-3576.
39. Ghosn J., Mazet A.A., Avettand-Fenoel V., Peytavin G., Wirden M., Delfraissy J.F., Chaix M.L. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen. J. Antimicrob. Chemother. 2009, 64:433-434.
40. Goethals O., Clayton R., Van Ginderen M., Vereycken I., Wagemans E., Geluykens P., Dockx K., Strijbos R., Smits V., Vos A., et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J. Virol. 2008, 82:10366-10374.
41. Goldgur Y., Dyda F., Hickman A.B., Jenkins T.M., Craigie R., Davies D.R. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc. Natl. Acad. Sci. USA 1998, 95:9150-9154.
42. Goldgur Y., Craigie R., Cohen G.H., Fujiwara T., Yoshinaga T., Fujishita T., Sugimoto H., Endo T., Murai H., Davies D.R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:13040-13043.
43. Greenwald J., Le V., Butler S.L., Bushman F.D., Choe S. The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. Biochemistry 1999, 38:8892-8898.
44. Grinsztejn B., Nguyen B.Y., Katlama C., Gatell J.M., Lazzarin A., Vittecoq D., Gonzalez C.J., Chen J., Harvey C.M., Isaacs R.D. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007, 369:1261-1269.
45. Grobler J.A., Stillmock K., Hu B., Witmer M., Felock P., Espeseth A.S., Wolfe A., Egbertson M., Bourgeois M., Melamed J., et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:6661-6666.
46. Guiot E., Carayon K., Delelis O., Simon F., Tauc P., Zubin E., Gottikh M., Mouscadet J.F., Brochon J.C., Deprez E. Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity. J. Biol. Chem. 2006, 281:22707-22719.
47. Hare S., Gupta S.S., Valkov E., Engelman A., Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464:232-236.
48. Hatano, H., Lampiris, H., Fransen, S., Gupta, S., Huang, W., Hoh, R., Martin, J.N., Lalezari, J., Bangsberg, D., Petropoulos, C., et al., 2010. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J. Acquir. Immune Defic. Syndr. (Epub ahead of print).
49. Hazuda D.J., Anthony N.J., Gomez R.P., Jolly S.M., Wai J.S., Zhuang L., Fisher T.E., Embrey M., Guare J.P., Egbertson M.S., et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:11233-11238.
50. Hazuda D.J., Felock P., Witmer M., Wolfe A., Stillmock K., Grobler J.A., Espeseth A., Gabryelski L., Schleif W., Blau C., et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287:646-650.
51. Karki R.G., Tang Y., Burke T.R., Nicklaus M.C. Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design. J. Comput. Aided Mol. Des. 2004, 18:739-760.
52. Kawasuji T., Fuji M., Yoshinaga T., Sato A., Fujiwara T., Kiyama R. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors. Bioorg. Med. Chem. 2006, 14:8420-8429.
53. Kawasuji T., Yoshinaga T., Sato A., Yodo M., Fujiwara T., Kiyama R. A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitors and modeling of hydrophilic and hydrophobic pharmacophores. Bioorg. Med. Chem. 2006, 14:8430-8445.
54. Langley D.R., Samanta H.K., Lin Z., Walker M.A., Krystal M.R., Dicker I.B. The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors. Biochemistry 2008, 47:13481-13488.
55. Lataillade M., Chiarella J., Kozal M.J. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir. Ther. 2007, 12:563-570.
56. Lee M.C., Deng J., Briggs J.M., Duan Y. Large-scale conformational dynamics of the HIV-1 integrase core domain and its catalytic loop mutants. Biophys. J. 2005, 88:3133-3146.
57. Lennox J., Dejesus E., Lazzarin A., Berger D., Pollard R., Madruga J., Zhao J., Gilbert C., Rodgers A., Teppler H., et al. Raltegravir demonstrates durable efficacy through 96 weeks: results from STARTMRK, a phase III study of raltegravir (RAL)-based vs efavirenz (EFV)-based therapy in treatment-naive HIV+ patients. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2009, (abstract #H-924b).
58. Lennox J.L., Dejesus E., Lazzarin A., Pollard R.B., Madruga J.V., Berger D.S., Zhao J., Xu X., Williams-Diaz A., Rodgers A.J., et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009, 374:796-806.
59. Lins R.D., Briggs J.M., Straatsma T.P., Carlson H.A., Greenwald J., Choe S., McCammon J.A. Molecular dynamics studies on the HIV-1 integrase catalytic domain. Biophys. J. 1999, 76:2999-3011.
60. Loizidou E.Z., Kousiappa I., Zeinalipour-Yazdi C.D., Van de Vijver D.A., Kostrikis L.G. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses. Biochemistry 2009, 48:4-6.
61. Long Y.Q., Jiang X.H., Dayam R., Sanchez T., Shoemaker R., Sei S., Neamati N. Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: implication for binding to two metal ions on the active site of integrase. J. Med. Chem. 2004, 47:2561-2573.
62. Lovell S., Goryshin I.Y., Reznikoff W.R., Rayment I. Two-metal active site binding of a Tn5 transposase synaptic complex. Nat. Struct. Biol. 2002, 9:278-281.
63. Maiga A.I., Malet I., Soulie C., Derache A., Koita V., Amellal B., Tchertanov L., Delelis O., Morand-Joubert L., Mouscadet J.F., et al. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. Antivir. Ther. 2009, 14:123-129.
64. Maignan S., Guilloteau J.P., Zhou-Liu Q., Clement-mella C., Mikol V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J. Mol. Biol. 1998, 282:359-368.
65. Malet I., Delelis O., Soulie C., Wirden M., Tchertanov L., Mottaz P., Peytavin G., Katlama C., Mouscadet J.F., Calvez V., et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J. Antimicrob. Chemother. 2009, 63:795-804.
66. Malet I., Delelis O., Valantin M.A., Montes B., Soulie C., Wirden M., Tchertanov L., Peytavin G., Reynes J., Mouscadet J.F., et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother. 2008, 52:1351-1358.
67. Marcelin A.G., Malet I., Fabeni L., Armenia D., Fourati S., Masquelier B., Katlama C., Perno C.F., Calvez T., Ceccherini-Silberstein F. Resistance-associated mutations to integrase inhibitor S/GSK1349572 in HIV-1 integrase inhibitor-naive and raltegravir-experienced patients. 17th Conference on Retroviruses and Opportunistic Infections (CROI) 2010, (abstract #554).
68. Marchand C., Johnson A.A., Karki R.G., Pais G.C., Zhang X., Cowansage K., Patel T.A., Nicklaus M.C., Burke T.R., Pommier Y. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol. Pharmacol. 2003, 64:600-609.
69. Markowitz M., Nguyen B.Y., Gotuzzo E., Mendo F., Ratanasuwan W., Kovacs C., Prada G., Morales-Ramirez J.O., Crumpacker C.S., Isaacs R.D., et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 2007, 46:125-133.
70. McColl D.J., Fransen S., Gupta S., Parkin N., Margot N., Chuck S., Cheng A.K., Miller M.D. Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137). Antivir. Ther. 2007, 12:S11-S111.
71. Metifiot, M., Maddali, K., Naumova, A., Zhang, X., Marchand, C., and Pommier, Y., 2010. Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir. Biochemistry (epub ahead of print).
72. Michel F., Crucifix C., Granger F., Eiler S., Mouscadet J.F., Korolev S., Agapkina J., Ziganshin R., Gottikh M., Nazabal A., et al. Structural basis for HIV-1 DNA integration in the human genome, role of the LEDGF/P75 cofactor. Embo J. 2009, 28:980-991.
73. Mouscadet J.F., Arora R., Andre J., Lambry J.C., Delelis O., Malet I., Marcelin A.G., Calvez V., Tchertanov L. HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations. J. Mol. Recognit. 2009, 22:480-494.
74. Nunthaboot N., Pianwanit S., Parasuk V., Ebalunode J.O., Briggs J.M., Kokpol S. Hybrid quantum mechanical/molecular mechanical molecular dynamics simulations of HIV-1 integrase/inhibitor complexes. Biophys. J. 2007, 93:3613-3626.
75. Pasquini S., Mugnaini C., Tintori C., Botta M., Trejos A., Arvela R.K., Larhed M., Witvrouw M., Michiels M., Christ F., Debyser Z., Corelli F. Investigations on the 4-quinolone-3-carboxylic acid motif. 1. Synthesis and structure-activity relationship of a class of human immunodeficiency virus type 1 integrase inhibitors. J. Med. Chem. 2008, 51:5125-5129.
76. Perryman A.L., Forli S., Morris G.M., Burt C., Cheng Y., Palmer M.J., Whitby K., McCammon J.A., Phillips C., Olson A.J. A dynamic model of HIV integrase inhibition and drug resistance. J. Mol. Biol. 2010, 397:600-615.
77. Podtelezhnikov A.A., Gao K., Bushman F.D., McCammon J.A. Modeling HIV-1 integrase complexes based on their hydrodynamic properties. Biopolymers 2003, 68:110-120.
78. Ren G., Gao K., Bushman F.D., Yeager M. Single-particle image reconstruction of a tetramer of HIV integrase bound to DNA. J. Mol. Biol. 2007, 366:286-294.
79. Rhee S.Y., Liu T.F., Kiuchi M., Zioni R., Gifford R.J., Holmes S.P., Shafer R.W. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 2008, 5:74.
80. Sato M., Motomura T., Aramaki H., Matsuda T., Yamashita M., Ito Y., Kawakami H., Matsuzaki Y., Watanabe W., Yamataka K., et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem. 2006, 49:1506-1508.
81. Savarino A., Pistello M., D'Ostilio D., Zabogli E., Taglia F., Mancini F., Ferro S., Matteucci D., De Luca L., Barreca M.L., et al. Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS. Retrovirology 2007, 4:79.
82. Seki T., Kobayashi M., Wakasa-Morimoto C., Yoshinaga T., Sato A., Fujiwara T., Underwood M.R., Garvey E.P., Johns B.A. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones. 17th Conference on Retroviruses and Opportunistic Infections (CROI) 2010, (abstract #555).
83. Serrao E., Odde S., Ramkumar K., Neamati N. Raltegravir, elvitegravir, and metoogravir: the birth of " me-too" HIV-1 integrase inhibitors. Retrovirology 2009, 6:25.
84. Shimura K., Kodama E., Sakagami Y., Matsuzaki Y., Watanabe W., Yamataka K., Watanabe Y., Ohata Y., Doi S., Sato M., et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 2008, 82:764-774.
85. Sichtig N., Sierra S., Kaiser R., Daumer M., Reuter S., Schulter E., Altmann A., Fatkenheuer G., Dittmer U., Pfister H., et al. Evolution of raltegravir resistance during therapy. J. Antimicrob. Chemother. 2009, 64:25-32.
86. Sotriffer C.A., Ni H., McCammon J.A. Active site binding modes of HIV-1 integrase inhibitors. J. Med. Chem. 2000, 43:4109-4117.
87. Steigbigel, R., Cooper, D., Eron, J., Gatell, J., Kumar, P., Rockstroh, J., Wan, H., Sklar, P., Teppler, H., Nguyen, B.-Y., and BENCHMRK-1 and 2 Study Groups, 2009. 96-week results from BENCHMRK 1 and 2, phase III studies of raltegravir in patients failing ART with triple-class-resistant HIV. 16th Conference on Retroviruses and Opportunistic Infections (CROI), Montreal, February 11-19 (abstract #571b).
88. Steigbigel R.T., Cooper D.A., Kumar P.N., Eron J.E., Schechter M., Markowitz M., Loutfy M.R., Lennox J.L., Gatell J.M., Rockstroh J.K., et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 2008, 359:339-354.
89. Summa V., Petrocchi A., Bonelli F., Crescenzi B., Donghi M., Ferrara M., Fiore F., Gardelli C., Gonzalez Paz O., Hazuda D.J., et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51:5843-5855.
90. Tchertanov L., Mouscadet J.F. Target recognition by catechols and beta-ketoenols: potential contribution of hydrogen bonding and Mn/Mg chelation to HIV-1 integrase inhibition. J. Med. Chem. 2007, 50:1133-1145.
91. Van Baelen K., Van Eygen V., Rondelez E., Stuyver L.J. Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS 2008, 22:1877-1880.
92. Vandeckerckhove L. GSK-1349572, a novel integrase inhibitor for the treatment of HIV infection. Curr. Opin. Invest. Drugs 2010, 11:203-212.
93. Wang J.Y., Ling H., Yang W., Craigie R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J. 2001, 20:7333-7343.
94. Wang L.D., Liu C.L., Chen W.Z., Wang C.X. Constructing HIV-1 integrase tetramer and exploring influences of metal ions on forming integrase-DNA complex. Biochem. Biophys. Res. Commun. 2005, 337:313-319.
95. Weber W., Demirdjian H., Lins R.D., Briggs J.M., Ferreira R., McCammon J.A. Brownian and essential dynamics studies of the HIV-1 integrase catalytic domain. J. Biomol. Struct. Dyn. 1998, 16:733-745.
96. Wielens J., Crosby I.T., Chalmers D.K. A three-dimensional model of the human immunodeficiency virus type 1 integration complex. J. Comput. Aided Mol. Des. 2005, 19:301-317.
97. Wijitkosoom A., Tonmunphean S., Truong T.N., Hannongbua S. Structural and dynamical properties of a full-length HIV-1 integrase: molecular dynamics simulations. J. Biomol. Struct. Dyn. 2006, 23:613-624.
98. Williams S.L., Essex J.W. Study of the conformational dynamics of the catalytic loop of WT and G140A/G149A HIV-1 integrase core domain using reversible digitally filtered molecular dynamics. J. Chem. Theory Comput. 2009, 5:411-421.
99. Wirden M., Simon A., Schneider L., Tubiana R., Malet I., Ait-Mohand H., Peytavin G., Katlama C., Calvez V., Marcelin A.G. Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug. J. Antimicrob. Chemother. 2009, 64:1087-1090.
100. Zhuang L., Wai J.S., Embrey M.W., Fisher T.E., Egbertson M.S., Payne L.S., Guare J.P., Vacca J.P., Hazuda D.J., Felock P.J., et al. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J. Med. Chem. 2003, 46:453-456.
101. Zolopa A.R., Berger D.S., Lampiris H., Zhong L., Chuck S.L., Enejosa J.V., Kearney B.P., Cheng A.K. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J. Infect. Dis. 2010, 201:814-822.